94 related articles for article (PubMed ID: 20498178)
1. Study of the efficacy and tolerability of 0.04% tretinoin microsphere gel for preadolescent acne.
Eichenfield LF; Matiz C; Funk A; Dill SW
Pediatrics; 2010 Jun; 125(6):e1316-23. PubMed ID: 20498178
[TBL] [Abstract][Full Text] [Related]
2. Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: a 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial.
Berger R; Rizer R; Barba A; Wilson D; Stewart D; Grossman R; Nighland M; Weiss J
Clin Ther; 2007 Jun; 29(6):1086-97. PubMed ID: 17692723
[TBL] [Abstract][Full Text] [Related]
3. Photographic assessment of tretinoin microsphere gel in moderate acne.
Feldman S; Nighland M
J Drugs Dermatol; 2008 Aug; 7(8 Suppl):s19-24. PubMed ID: 18724651
[TBL] [Abstract][Full Text] [Related]
4. Tretinoin microsphere gel pump 0.04% versus tazarotene cream 0.05% in the treatment of mild-to-moderate facial acne vulgaris.
Kircik LH
J Drugs Dermatol; 2009 Jul; 8(7):650-4. PubMed ID: 19588641
[TBL] [Abstract][Full Text] [Related]
5. Tretinoin microsphere gel in facial acne vulgaris: a meta-analysis.
Nighland M; Grossman R
J Drugs Dermatol; 2008 Aug; 7(8 Suppl):s2-8. PubMed ID: 18724648
[TBL] [Abstract][Full Text] [Related]
6. Tretinoin microsphere gel 0.04% pump for treating acne vulgaris in preadolescents: a randomized, controlled study.
Eichenfield LF; Hebert AA; Schachner L; Paller AS; Rossi AB; Lucky AW
Pediatr Dermatol; 2012; 29(5):598-604. PubMed ID: 22712470
[TBL] [Abstract][Full Text] [Related]
7. Phase 4 study to assess tretinoin pump for the treatment of facial acne.
Eichenfield LF; Nighland M; Rossi AB; Cook-Bolden F; Grimes P; Fried R; Levy S;
J Drugs Dermatol; 2008 Dec; 7(12):1129-36. PubMed ID: 19137766
[TBL] [Abstract][Full Text] [Related]
8. Tretinoin microsphere gel in younger acne patients.
Jorizzo J; Grossman R; Nighland M
J Drugs Dermatol; 2008 Aug; 7(8 Suppl):s9-13. PubMed ID: 18724649
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne.
Richter JR; Förström LR; Kiistala UO; Jung EG
J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):227-33. PubMed ID: 9883434
[TBL] [Abstract][Full Text] [Related]
10. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate and Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability.
Stein Gold L; Pariser DM; Guenin E
J Drugs Dermatol; 2019 Dec; 18(12):1218-1225. PubMed ID: 31860209
[TBL] [Abstract][Full Text] [Related]
11. Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris.
Tanghetti E; Dhawan S; Torok H; Kircik L
Dermatol Online J; 2007 Jul; 13(3):1. PubMed ID: 18328195
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females.
Harper JC; Baldwin H; Stein Gold L; Guenin E
J Drugs Dermatol; 2019 Nov; 18(11):1147-1154. PubMed ID: 31741360
[TBL] [Abstract][Full Text] [Related]
13. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population.
Eichenfield LF; Sugarman JL; Guenin E; Harris S; Bhatt V
Pediatr Dermatol; 2019 Mar; 36(2):193-199. PubMed ID: 30656753
[TBL] [Abstract][Full Text] [Related]
14. Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population.
Cook-Bolden FE; Weinkle SH; Guenin E; Bhatt V
J Drugs Dermatol; 2019 Jan; 18(1):32-38. PubMed ID: 30681791
[TBL] [Abstract][Full Text] [Related]
15. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population.
Han G; Armstrong AW; Desai SR; Guenin E
J Drugs Dermatol; 2019 Sep; 18(9):910-916. PubMed ID: 31524347
[TBL] [Abstract][Full Text] [Related]
16. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Impact of Gender and Race on Efficacy and Safety.
Lain E; Day D; Harper J; Guenin E
J Drugs Dermatol; 2019 Nov; 18(11):1128-1138. PubMed ID: 31741356
[TBL] [Abstract][Full Text] [Related]
17. Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-Severe Acne Vulgaris in an Adult and Adolescent Female Population.
Kircik LH; Baldwin H; Lain E; Guenin E; Harris S; Bhatt V
J Drugs Dermatol; 2019 Feb; 18(2):178-188. PubMed ID: 30811141
[TBL] [Abstract][Full Text] [Related]
18. Tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for treatment of acne vulgaris: morning/morning regimen is as effective and safe as morning/evening regimen.
Pariser D; Bucko A; Fried R; Jarratt MT; Kempers S; Kircik L; Lucky AW; Rafal E; Rendon M; Weiss J; Wilson DC; Rossi AB; Ramaswamy R; Nighland M
J Drugs Dermatol; 2010 Jul; 9(7):805-13. PubMed ID: 20677537
[TBL] [Abstract][Full Text] [Related]
19. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults.
Berger R; Barba A; Fleischer A; Leyden JJ; Lucky A; Pariser D; Rafal E; Thiboutot D; Wilson D; Grossman R; Nighland M
Cutis; 2007 Aug; 80(2):152-7. PubMed ID: 17944177
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris.
Marazzi P; Boorman GC; Donald AE; Davies HD
J Dermatolog Treat; 2002 Sep; 13(3):111-7. PubMed ID: 12227873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
